Figure 5.

Antibodies highly recognising ZIKV E epitopes have a non‐specific role during ZIKV infection. Neutralising capability of pooled mouse sera from (a) type I IFN‐competent or (b) MAR1‐5A3‐treated WT animals upon depletion of ZIKV‐specific antibodies targeting peptides that are either common epitope: P4, type I IFN‐competent dominant epitopes: P5, P6 or P21, or MAR1‐5A3‐treated dominant epitopes: P8 or P13. A non‐specific peptide control, OVA, was also included. Neutralisation assays were performed at 0.5 µg mL⁻¹ of ZIKV‐specific IgG. Data are represented as mean ± SEM of two independent experiments with five animals per group per experiment. Results are expressed as log₂ fold change relative to the respective non‐depleted controls. (c) A two‐tailed paired t‐test analysis on the neutralising capability of pooled mouse sera from either type I IFN‐competent or MAR1‐5A3‐treated animals after depletion of ZIKV‐specific antibodies targeting peptides P4, P5, P6, P8, P13, P21 and OVA.